- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365454
NEXUS™ Aortic Arch Stent Graft System First In Man Study
Feasibility Clinical Study to Evaluate the Safety and Performance of the NEXUS™ Aortic Arch Stent Graft System
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of the study is to evaluate the safety and performance of the Nexus™ Aortic Arch Stent Graft System for the endovascular treatment of thoracic aortic pathologies requiring landing in the Aortic Arch (zone 0, zone 1, zone 2).
The Nexus™ Aortic Arch Stent Graft System is indicated for the endovascular treatment of thoracic aortic pathologies involving the aortic arch (such as aneurisms and dissections). The Nexus™ is intended to exclude the lesion from the blood circulation in patients diagnosed with thoracic aortic pathology and who have appropriate anatomy to accommodate the Nexus™ system in an endovascular procedure.
The primary objectives of the study are to evaluate the safety and performance of the Nexus™ Aortic Arch Aneurysm Stent Graft System.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hradec Králové, Czechia, 500 05
- Faculty Hospital Hradec Kralove
-
-
-
-
-
Rome, Italy, 00135
- San Filippo Neri Hospital
-
-
-
-
-
Zurich, Switzerland, 8091
- Zurich University Hospital
-
-
Witellikerstrasse 40
-
Zürich, Witellikerstrasse 40, Switzerland, CH-8032
- Klinic Hirslanden
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female age ≥ 18.
- Any Thoracic Aorta pathology requiring landing in the Aortic Arch (zone 0, zone 1, zone2), e.g. aneurysm, dissection, false/Pseudo aneurysm.
- In patient with a thoracic aneurysm: dilatation of the aortic arch larger than 5.5cm in diameter, or symptomatic aneurysm of the aortic arch, or aortic diameter growth rate > 5mm per 6 months
- Patient is considered an appropriate candidate for an elective surgery, as evaluated by Physical Status Classification System I, II or III (American Society of Anesthesiologists).
- Femoral artery diameter as documented by CTA or MRA that allows endovascular access to the diseased site with a 20-22Fr delivery catheter.
- Access vessels morphology suitable for endovascular repair in terms of tortuosity, calcification and angulation, documented by CTA, MRA.
- Access vessel (femoral/iliac) diameter > 7 mm
- Ascending Aorta landing zone length > 30 mm
- Brachial/Axial Artery diameter > 3 mm
- Patient understands and is voluntarily willing to participate as evidenced by personally signing the Informed Consent document, and willingness to comply with follow-up schedule
Exclusion Criteria:
- Female is of childbearing potential
- Life expectancy of less than 1 year
- Any medical condition that, according to the investigator's decision, might expose the patient to increased risk by the investigational device or procedure.
- Acutely ruptured or instable aneurysm or an acute vascular injury due to trauma or infected penetrating ulcers of the aorta.
- Patient with an increased risk for aneurysm rupture during the procedure.
- Patient whose arterial access site is not anticipated to accommodate the access of the Nexus™ Delivery System, due to size, tortuosity or hostile groins (scarring, obesity, or previous failed puncture)
- Patients with severe atherosclerosis or intraluminal thrombus of the aorta or in the BCT
- Patient is suffering from unstable angina or NYHA classification III and IV and/or ASA classification IV and above.
- Patient has had a myocardial infarction (MI) or cerebral vascular accident (CVA) within 3 months prior to the planned implantation
- Patient has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment.
- Patient with a contraindication to undergo angiography
- Patient with known sensitivities or allergies to the device materials- Nitinol and polyester
- Clinical conditions that severely inhibit x-ray visualization of the Aorta.
- Connective tissue disease (e.g., Marfan's or Ehler's-Danlos syndromes)
- Patient has history of bleeding diathesis or coagulopathy that may limit the use of dual antiplatelet or anticoagulant therapy by the decision of the investigator
- Patient has an active systemic infection at the time of the procedure documented by pain, fever, drainage, positive culture and/or leukocytosis (WBC > 11,000 mm3).
- Patients who have the condition that threatens to infect the stent graft.
- Acute renal failure; chronic renal failure (excluding dialysis); Creatinine > 2.00 mg/dl or > 182 umol/L
- Patient underwent major surgery or interventional procedure in the last three months.
- Any other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, or the procedures and evaluations pre- and post- treatment.
- Active participation in another clinical trial that is reasonable to conflict with the NexusTM study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Thoracic Aortic Disease Single Arm Study
Thoracic Aortic Disease treated by Stent Graft Placement
|
The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via "surgical bypass grafting", either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery. This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Device related mortality at 30 days post implantation
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Device related re-intervention within 1 year from implantation
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Performance: Assess the rate of successful disease treatment at 30 days post implantation
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mario Lachat, Prof. MD, Klinic Hirslanden, Switzerland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP004.00
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thoracic Aortic Aneurysm
-
Cook Research IncorporatedCompletedDescending Thoracic Aortic AneurysmUnited States, Canada
-
Medtronic CardiovascularMedtronicTerminatedThoracic Aortic AneurysmsUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States
-
Wuhan Asia Heart HospitalFu Wai Hospital, Beijing, ChinaCompletedDissection of Aorta, Thoracic | Aneurysm of Aorta, ThoracicChina
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Duke Vascular, Inc.Unknown
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmsUnited States, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedThoracic Aortic AneurysmFrance
-
Universitaire Ziekenhuizen KU LeuvenRecruitingThoracic Aortic AneurysmsBelgium
-
W.L.Gore & AssociatesRecruitingThoracic Aortic Aneurysm | Abdominal Aortic AneurysmSpain, Denmark, Italy, Norway, Netherlands, Sweden
Clinical Trials on Stent Graft Placement (Nexus)
-
Endospan Ltd.RecruitingAortic Aneurysm | Aortic Dissection | Penetrating Aortic Ulcer | Intramural HematomaUnited States, New Zealand
-
Endospan Ltd.Completed
-
Merit Medical Systems, Inc.CompletedVenous Stenosis | Venous OcclusionUnited Kingdom, Greece
-
University Hospital of PatrasNot yet recruitingStudy Focuses on the Use of Covered Stents (Stent Grafts) for the Treatment of Dysfunctional Vascular Access of Hemodialysis Patients
-
Merit Medical Systems, Inc.WithdrawnPeripheral Arterial Disease | Iliac Artery Occlusion | Iliac Artery Disease | Stenosis of Artery
-
Texas Vascular AssociatesW.L.Gore & AssociatesCompletedAtherosclerosis | Claudication | Lower Extremity Ischemia | Rest PainUnited States
-
Xijing HospitalChanghai HospitalUnknown
-
Xijing HospitalChanghai Hospital; Shanghai Zhongshan HospitalUnknown
-
Xijing HospitalUnknown
-
Lombard MedicalSuspendedAbdominal Aortic AneurysmsUnited Kingdom, Germany, New Zealand, Spain, Czechia, Italy